Heron Therapeutics Inc
NASDAQ:HRTX

  • LAST PRICE
    2.0600
  • TODAY'S CHANGE (%)
    0.0400 (1.9802%)
  • Bid / Lots
    2.0700/ 4
  • Ask / Lots
    2.1000/ 1
  • Open / Previous Close
    2.0200 / 2.0200
  • Day Range
    1.9300
    2.0600
  • 52 Week Range
    0.5000
    3.9300
  • Volume
    6,724,274

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Sep 3, 2024

      Show headlines and story abstract

    • 8:00AM ET on Tuesday Sep 03, 2024 by PR Newswire
      Companies Mentioned: HRTX

      Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, announced today the appointment ofBrett Fleshmanas Chief Business Officer.Mr. Fleshmanwill contribute his 25 years of experience in corporate and business development, commercial strategy, and marketing of pharmaceuticals, biologics, and surgical devices to the management team enabling the next phase of growth.

    • 8:00AM ET on Tuesday Sep 03, 2024 by Dow Jones
      Companies Mentioned: HRTX

      Heron Therapeutics Announces Appointment of Brett Fleshman as Chief Business Officer

      PR Newswire

      SAN DIEGO, Sept. 3, 2024

      SAN DIEGO, Sept. 3, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, announced today the appointment of Brett Fleshman as Chief Business Officer. Mr. Fleshman will contribute his 25 years of experience in corporate and business development, commercial strategy, and marketing of pharmaceuticals, biologics, and surgical devices to the management team enabling the next phase of growth.

    • 8:00AM ET on Tuesday Sep 03, 2024 by Dow Jones
      Companies Mentioned: HRTX

      Heron Therapeutics Announces Appointment of Brett Fleshman as Chief Business Officer

      PR Newswire

      SAN DIEGO, Sept. 3, 2024

      SAN DIEGO, Sept. 3, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, announced today the appointment of Brett Fleshman as Chief Business Officer. Mr. Fleshman will contribute his 25 years of experience in corporate and business development, commercial strategy, and marketing of pharmaceuticals, biologics, and surgical devices to the management team enabling the next phase of growth.

Peers Headlines